You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antibody

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Assess New Participant's Perspectives Beyond Clinical Efficacy

Not yet recruiting
  • Multiple Sclerosis, Relapsing-Remitting
    • (no location specified)
    Nov 7, 2023

    Respiratory Tract Infections Trial (Respiratory pathogen panel PCR test, COVID-19 antibody test)

    Not yet recruiting
    • Respiratory Tract Infections
    • Respiratory pathogen panel PCR test
    • COVID-19 antibody test
    • (no location specified)
    May 8, 2023

    Lung Cancer Trial in Houston (Cemiplimab, Kevzara (Sarilumab))

    Not yet recruiting
    • Lung Cancer
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 19, 2023

    Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5

    Completed
    • Paroxysmal Nocturnal Hemoglobinuria
    • Anti-C5 antibody treatment
    • Paris, France
      AP-HP Hôpital Saint Louis
    Apr 24, 2023

    Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC:

    Not yet recruiting
    • Hepatocellular Carcinoma Non-resectable
    • transarterial therapies
    • (no location specified)
    Nov 27, 2022

    Atopic Dermatitis Trial in Shanghai (MG-K10/Placebo)

    Active, not recruiting
    • Atopic Dermatitis
    • MG-K10/Placebo
    • Shanghai, China
      Huashan Hospital Affiliated to Fudan University
    Aug 31, 2023

    Advanced Solid Tumor Trial in Bengbu (HB0030 injection)

    Recruiting
    • Advanced Solid Tumor
    • HB0030 injection
    • Bengbu, Anhui, China
      the First Affiliated Hospital of Bengbu Medical College
    Jan 20, 2023

    HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,

    Completed
    Has Results
    • HER2 Positive Breast Carcinoma
    • +6 more
    • Palo Alto, California
      Stanford University, School of Medicine
    Sep 22, 2022

    Acquired Hemophilia Trial in Tianjin (Daratumumab)

    Recruiting
    • Acquired Hemophilia
    • Tianjin, China
      Chinese Academy of Medical Science and Blood Disease Hospital
    May 5, 2023

    Colorectal Cancer Trial (Administration of CC-3)

    Not yet recruiting
    • Colorectal Cancer
    • Administration of CC-3
    • (no location specified)
    Aug 11, 2023

    Antibody-mediated Rejection Trial in Vienna, Berlin (Felzartamab, Placebo)

    Recruiting
    • Antibody-mediated Rejection
    • Vienna, Austria
    • +1 more
    Aug 23, 2022

    COVID-19 Trial in New Taipei City (Covid19 Vaccination dose)

    Recruiting
    • COVID-19
    • Covid19 Vaccination dose
    • New Taipei City, Taiwan
      TuCheng Hospital
    Apr 24, 2023

    Helicobacter Pylori Infection Trial in Changsha (Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone,

    Recruiting
    • Helicobacter Pylori Infection
    • Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth
    • +3 more
    • Changsha, Hunan, China
      The Third Xiangya Hospital of Central South University
    Dec 6, 2022

    SARS-CoV2 Infection Trial in Flint (General SARS-CoV-2 Communication, Rural-Targeted SARS-CoV-2 Communication)

    Recruiting
    • SARS-CoV2 Infection
    • General SARS-CoV-2 Communication
    • Rural-Targeted SARS-CoV-2 Communication
    • Flint, Michigan
      Flint Journal Building
    Oct 10, 2023

    Profiling Spike Protein Antibody Response Post COVID Booster

    Not yet recruiting
    • SARS-CoV-2 Booster
    • Spike Protein IgG Antibody
    • Obtain antibody titers
    • (no location specified)
    Jul 25, 2022

    MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)

    Not yet recruiting
    • MSS
    • Rectal Cancer
    • Sintilimab with Interleukin-2
    • (no location specified)
    Nov 1, 2023

    Secondary Antibody Deficiency Trial (Immunoglobulin replacement therapy (IGRT))

    Not yet recruiting
    • Secondary Antibody Deficiency
    • Immunoglobulin replacement therapy (IGRT)
    • (no location specified)
    Nov 4, 2022

    Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

    Recruiting
    • Solid Tumor, Adult
    • +4 more
    • KRAS-EphA-2-CAR-DC
    • +3 more
    • Beijing, Beijing, China
      Biotherapeutic Department of Chinsese PLA Gereral Hospital
    Nov 29, 2022

    Associated With Antiphospholipid Antibody Syndrome

    Recruiting
    • Antiphospholipid Syndrome
      • Durham, North Carolina
        Duke University Medical Center
      Jan 24, 2023

      Diabetic Polyneuropathy Trial in Rochester, Aarhus, Copenhagen (Eptinezumab, Placebo)

      Not yet recruiting
      • Diabetic Polyneuropathy
      • Rochester, Minnesota
      • +2 more
      Jun 30, 2023

      Patients Pregnant or Without Primary Antiphospholipid Antibody

      Recruiting
      • Preeclampsia
      • +5 more
      • Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)
      • Milan, Italy
        San Raffaele Hospital
      Mar 28, 2023

      Neoadjuvant Chemo, PD-1 Antibody, Radiotherapy Trial (neoadjuvant chemo combined with PD-1 antibody + radical radiotherapy)

      Not yet recruiting
      • Neoadjuvant Chemotherapy
      • +3 more
      • neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
      • (no location specified)
      Sep 21, 2022

      Against SARS-CoV-2 (COVID-19)in Dazhu County in 2023

      Recruiting
      • COVID-19
        • Dazhou, Sichuan, China
          Dazhu County Center for Disease Control and Prevention
        Mar 7, 2023

        Acute Gout Trial in Wuhan, Linyi, Shanghai (Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection 100 mg (phase Ib),

        Recruiting
        • Acute Gout
        • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
        • +6 more
        • Wuhan, Hubei, China
        • +2 more
        Oct 17, 2022

        Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)

        Withdrawn
        • Relapsed Solid Neoplasm
        • +2 more
        • STI-3258
        • (no location specified)
        Jan 24, 2023